Documenti full-text disponibili:
      
        
          
            | ![demuro_stefania_tesi.pdf [thumbnail of demuro_stefania_tesi.pdf]](https://amsdottorato.unibo.it/style/images/fileicons/application_pdf.png) | Documento PDF (English)
 - Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
 Download (16MB)
 | 
        
      
    
  
  
    
      Abstract
      Neuronal microtubules assembly and dynamics are regulated by several proteins including (MT)-associated protein tau, whose aberrant hyperphosphorylation promotes its dissociation from MTs and its abnormal deposition into neurofibrillary tangles, a common neurotoxic hallmarks of neurodegenerative tauopathies. To date, no disease-modifying drugs have been approved to combat CNS tau-related diseases. The multifactorial etiology of these conditions represents one of the major limits in the discovery of effective therapeutic options. In addition, tau protein functions are orchestrated by diverse post-translational modifications among which phosphorylation mediated by PKs plays a leading role. In this context, conventional single-target therapies are often inadequate in restoring perturbed networks and fraught with adverse side-effects. This thesis reports two distinct approaches to hijack MT defects in neurons. The first is focused on the rational design and synthesis of first-in-class triple inhibitors of GSK-3β, FYN, and DYRK1A, three close-related PKs, which act as master regulators of aberrant tau hyperphosphorylation. A merged multi-target pharmacophore strategy was applied to simultaneously modulate all three targets and achieve a disease-modifying effect. Optimization of ARN25068 by a computationally and crystallographic driven SAR exploration, allowed to rationalize the key structural modifications to maintain a balanced potency against all three targets and develop a new generation of quite well-balanced analogs exhibiting improved physicochemical properties, a good in vitro ADME profile, and promising cell-based anti-tau phosphorylation activity.
In Part II, MT-stabilizing compounds have been developed to compensate MT defects in tau-related pathologies. Intensive chemical effort has been devoted to scaling up BL-0884, identified as a promising MT-normalizing TPD, which exhibited favorable ADME-PK, including brain penetration, oral bioavailability, and brain pharmacodynamic activity. A suitable functionalization of the exposed hydroxyl moiety of BL-0884 was carried out to generate corresponding esters and amides possessing a wide range of applications as prodrugs and active targeting for cancer chemotherapy.
     
    
      Abstract
      Neuronal microtubules assembly and dynamics are regulated by several proteins including (MT)-associated protein tau, whose aberrant hyperphosphorylation promotes its dissociation from MTs and its abnormal deposition into neurofibrillary tangles, a common neurotoxic hallmarks of neurodegenerative tauopathies. To date, no disease-modifying drugs have been approved to combat CNS tau-related diseases. The multifactorial etiology of these conditions represents one of the major limits in the discovery of effective therapeutic options. In addition, tau protein functions are orchestrated by diverse post-translational modifications among which phosphorylation mediated by PKs plays a leading role. In this context, conventional single-target therapies are often inadequate in restoring perturbed networks and fraught with adverse side-effects. This thesis reports two distinct approaches to hijack MT defects in neurons. The first is focused on the rational design and synthesis of first-in-class triple inhibitors of GSK-3β, FYN, and DYRK1A, three close-related PKs, which act as master regulators of aberrant tau hyperphosphorylation. A merged multi-target pharmacophore strategy was applied to simultaneously modulate all three targets and achieve a disease-modifying effect. Optimization of ARN25068 by a computationally and crystallographic driven SAR exploration, allowed to rationalize the key structural modifications to maintain a balanced potency against all three targets and develop a new generation of quite well-balanced analogs exhibiting improved physicochemical properties, a good in vitro ADME profile, and promising cell-based anti-tau phosphorylation activity.
In Part II, MT-stabilizing compounds have been developed to compensate MT defects in tau-related pathologies. Intensive chemical effort has been devoted to scaling up BL-0884, identified as a promising MT-normalizing TPD, which exhibited favorable ADME-PK, including brain penetration, oral bioavailability, and brain pharmacodynamic activity. A suitable functionalization of the exposed hydroxyl moiety of BL-0884 was carried out to generate corresponding esters and amides possessing a wide range of applications as prodrugs and active targeting for cancer chemotherapy.
     
  
  
    
    
      Tipologia del documento
      Tesi di dottorato
      
      
      
      
        
      
        
          Autore
          Demuro, Stefania
          
        
      
        
          Supervisore
          
          
        
      
        
          Co-supervisore
          
          
        
      
        
          Dottorato di ricerca
          
          
        
      
        
      
        
          Ciclo
          35
          
        
      
        
          Coordinatore
          
          
        
      
        
          Settore disciplinare
          
          
        
      
        
          Settore concorsuale
          
          
        
      
        
          Parole chiave
          Microtubules, Central nervous system, Multitarget, Protein kinases, Tauopathies, MT-stabilizers, Alzheimer's Disease
          
        
      
        
          URN:NBN
          
          
        
      
        
          DOI
          10.48676/unibo/amsdottorato/10775
          
        
      
        
          Data di discussione
          16 Giugno 2023
          
        
      
      URI
      
      
     
   
  
    Altri metadati
    
      Tipologia del documento
      Tesi di dottorato
      
      
      
      
        
      
        
          Autore
          Demuro, Stefania
          
        
      
        
          Supervisore
          
          
        
      
        
          Co-supervisore
          
          
        
      
        
          Dottorato di ricerca
          
          
        
      
        
      
        
          Ciclo
          35
          
        
      
        
          Coordinatore
          
          
        
      
        
          Settore disciplinare
          
          
        
      
        
          Settore concorsuale
          
          
        
      
        
          Parole chiave
          Microtubules, Central nervous system, Multitarget, Protein kinases, Tauopathies, MT-stabilizers, Alzheimer's Disease
          
        
      
        
          URN:NBN
          
          
        
      
        
          DOI
          10.48676/unibo/amsdottorato/10775
          
        
      
        
          Data di discussione
          16 Giugno 2023
          
        
      
      URI
      
      
     
   
  
  
  
  
  
    
    Statistica sui download
    
    
  
  
    
      Gestione del documento: 
      
        